Intended for European healthcare professionals only
Intended for European healthcare professionals only
Expert perspectives icon

Expert perspectives on cholangiocarcinoma (CCA)

Enhance your knowledge of CCA by listening to experts give their
perspectives on key topics in the educational videos below.*

Cholangiocarcinoma: Under the spotlight

This online webinar took place on 26 February 2021 and was hosted by our esteemed faculty
who critically discussed the complexity of diagnosing CCA and the clinical and genetic
heterogeneity associated with the disease.

Dr Teresa Macarulla
Dr Teresa Macarulla
Vall d’Hebron University Hospital,
Barcelona, Spain
Dr Joachim Mertens
Dr Joachim Mertens
University Hospital Zürich,
Zürich, Switzerland
Dr Angela Lamarca
Dr Angela Lamarca
The Christie NHS Foundation Trust,
Manchester, UK
Dr Coralie Sayag
Dr Coralie Sayag
Medical Director Solid Tumors, Region Europe,
Incyte Biosciences International Sàrl
Education Icon

Educational highlights and quiz

Watch the five educational videos below and answer the quiz questions to enhance your knowledge of CCA.

Overview of CCA

Professor Bruno Sangro
Professor Bruno Sangro
Director, Liver Unit & Co-Director, HPB Oncology Area,
Clinica Universidad de Navarra, Pamplona, Spain
Although rare, the incidence of CCA, in particular intrahepatic CCA, is generally increasing worldwide
REFERENCE: Bañales JM, et al. Nat Rev Gastroenterol Hepatol. 2016;13:261–80.
Question Mark
Answer the question below
Approximately, what is the 5-year overall survival rate for patients with CCA? (Select one)

Unmet needs in CCA

Helen Morement
Helen Morement
CEO and Founder of AMMF - The Cholangiocarcinoma Charity, London, UK
70% of patients with CCA are diagnosed with advanced disease, which compromises therapeutic options and leads to a poor prognosis
REFERENCE: Bañales JM, et al. Nat Rev Gastroenterol Hepatol. 2020;17:557–88.
Question Mark
Answer the question below
What key unmet needs are associated with CCA? (Select all that apply)

Importance of the multidisciplinary team (MDT)
in CCA diagnosis and treatment

Professor Lorenza Rimassa
Professor Lorenza Rimassa
Associate Professor of Medical Oncology, Humanitas University and Humanitas Research Hospital-IRCCS, Milan, Italy
Helen Morement
Helen Morement
CEO and Founder of AMMF - The Cholangiocarcinoma Charity, London, UK
Professor Juan Valle
Professor Juan Valle
University of Manchester/The Christie, Manchester, UK
Professor Peter Schirmacher
Professor Peter Schirmacher
Institute of Pathology, University Hospital Heidelberg
A multidisciplinary team approach enables a more comprehensive understanding of disease biology and collaboration options for patients with CCA
REFERENCE: Patel T. Nat Rev Gastroenterol Hepatol. 2011;8:189–200.
Question Mark
Answer the question below
Patients with CCA are often misdiagnosed with cancers of unknown primary – true or false?

Importance of performing biopsies in patients with CCA

Professor Lorenza Rimassa
Professor Lorenza Rimassa
Associate Professor of Medical Oncology, Humanitas University and Humanitas Research Hospital-IRCCS, Milan, Italy
Helen Morement
Helen Morement
CEO and Founder of AMMF - The Cholangiocarcinoma Charity, London, UK
Professor Juan Valle
Professor Juan Valle
University of Manchester/The Christie, Manchester, UK
Professor Peter Schirmacher
Professor Peter Schirmacher
Institute of Pathology, University Hospital Heidelberg
Biopsy technique should account for planned molecular profiling as well as diagnostic needs
REFERENCE: Cree IA, et al. J Clin Pathol. 2014;67:923–31
Question Mark
Answer the question below
What percentage of patients with CCA present with advanced disease, for which a biopsy should be considered mandatory? (Select one)

Importance of molecular profiling in patients with CCA

Professor Lorenza Rimassa
Professor Lorenza Rimassa
Associate Professor of Medical Oncology, Humanitas University and Humanitas Research Hospital-IRCCS, Milan, Italy
Helen Morement
Helen Morement
CEO and Founder of AMMF - The Cholangiocarcinoma Charity, London, UK
Professor Juan Valle
Professor Juan Valle
University of Manchester/The Christie, Manchester, UK
Professor Peter Schirmacher
Professor Peter Schirmacher
Institute of Pathology, University Hospital Heidelberg
50% of patients with CCA have at least one potentially actionable genomic alterations, supporting the rationale for molecular profiling at diagnosis
REFERENCE: Lowery MA, et al. Clin Cancer Res. 2018;24:4154–61.
Question Mark
Answer the question below
For which patients with CCA should molecular profiling be considered? (Select all that apply)